21995845|t|Dopamine and alpha-synuclein dysfunction in Smad3 null mice.
21995845|a|BACKGROUND: Parkinson's disease (PD) is characterized by dopaminergic neurodegeneration in the substantia nigra (SN). Transforming growth factor-beta1 (TGF-beta1) levels increase in patients with PD, although the effects of this increment remain unclear. We have examined the mesostriatal system in adult mice deficient in Smad3, a molecule involved in the intracellular TGF-beta1 signalling cascade. RESULTS: Striatal monoamine oxidase (MAO)-mediated dopamine (DA) catabolism to 3,4-dihydroxyphenylacetic acid (DOPAC) is strongly increased, promoting oxidative stress that is reflected by an increase in glutathione levels. Fewer astrocytes are detected in the ventral midbrain (VM) and striatal matrix, suggesting decreased trophic support to dopaminergic neurons. The SN of these mice has dopaminergic neuronal degeneration in its rostral portion, and the pro-survival Erk1/2 signalling is diminished in nigra dopaminergic neurons, not associated with alterations to p-JNK or p-p38. Furthermore, inclusions of alpha-synuclein are evident in selected brain areas, both in the perikaryon (SN and paralemniscal nucleus) or neurites (motor and cingulate cortices, striatum and spinal cord). Interestingly, these alpha-synuclein deposits are detected with ubiquitin and P(S129)-alpha-synuclein in a core/halo cellular distribution, which resemble those observed in human Lewy bodies (LB). CONCLUSIONS: Smad3 deficiency promotes strong catabolism of DA in the striatum (ST), decrease trophic and astrocytic support to dopaminergic neurons and may induce alpha-synuclein aggregation, which may be related to early parkinsonism. These data underline a role for Smad3 in alpha-synuclein and DA homeostasis, and suggest that modulatory molecules of this signalling pathway should be evaluated as possible neuroprotective agents.
21995845	0	8	Dopamine	Chemical	MESH:D004298
21995845	13	28	alpha-synuclein	Gene	20617
21995845	44	49	Smad3	Gene	17127
21995845	55	59	mice	Species	10090
21995845	73	92	Parkinson's disease	Disease	MESH:D010300
21995845	94	96	PD	Disease	MESH:D010300
21995845	118	148	dopaminergic neurodegeneration	Disease	MESH:D009422
21995845	179	211	Transforming growth factor-beta1	Gene	7040
21995845	213	222	TGF-beta1	Gene	7040
21995845	243	251	patients	Species	9606
21995845	257	259	PD	Disease	MESH:D010300
21995845	366	370	mice	Species	10090
21995845	384	389	Smad3	Gene	17127
21995845	432	441	TGF-beta1	Gene	21803
21995845	513	521	dopamine	Chemical	MESH:D004298
21995845	523	525	DA	Chemical	MESH:D004298
21995845	541	571	3,4-dihydroxyphenylacetic acid	Chemical	MESH:D015102
21995845	573	578	DOPAC	Chemical	MESH:D015102
21995845	666	677	glutathione	Chemical	MESH:D005978
21995845	844	848	mice	Species	10090
21995845	853	887	dopaminergic neuronal degeneration	Disease	MESH:D009410
21995845	933	939	Erk1/2	Gene	26417;26413
21995845	1033	1036	JNK	Gene	26419
21995845	1042	1045	p38	Gene	26416
21995845	1074	1089	alpha-synuclein	Gene	6622
21995845	1272	1287	alpha-synuclein	Gene	6622
21995845	1337	1352	alpha-synuclein	Gene	6622
21995845	1424	1429	human	Species	9606
21995845	1430	1441	Lewy bodies	Disease	MESH:D020961
21995845	1443	1445	LB	Disease	MESH:D020961
21995845	1461	1466	Smad3	Gene	17127
21995845	1508	1510	DA	Chemical	MESH:D004298
21995845	1612	1627	alpha-synuclein	Gene	6622
21995845	1671	1683	parkinsonism	Disease	MESH:D010302
21995845	1717	1722	Smad3	Gene	17127
21995845	1726	1741	alpha-synuclein	Gene	20617
21995845	1746	1748	DA	Chemical	MESH:D004298
21995845	Association	17127	20617
21995845	Association	MESH:D004298	17127
21995845	Association	17127	6622
21995845	Association	MESH:D010302	17127
21995845	Positive_Correlation	MESH:D010300	7040
21995845	Association	MESH:D010300	6622
21995845	Association	17127	21803
21995845	Association	MESH:D004298	MESH:D015102
21995845	Association	MESH:D020961	6622
21995845	Association	MESH:D010302	6622

